CVS program seeks to encourage genetic testing of cancer patients

CVS is addressing the disconnect between availability of targeted cancer therapies and limited access to genetic tests through a precision medicine program that encourages next generation sequencing at the point of diagnosis.

The CVS Health Corp. (NYSE:CVS) program, dubbed Transform Oncology Care, is offered through an online provider portal that makes NGS panels available to providers at the point of diagnosis, and uses the genomic test results at the point of prescribing to connect patients with the appropriate therapies as quickly as possible. ...